Angiogenesis in acute myeloid leukemia and opportunities for novel therapies

Journal of Oncology

Volumn , Issue , 2012, Pages

  Trujillo, Angelica ^a   McGee, Christie ^a   Cogle, Christopher R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CEDIRANIB; COLCHICINE; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; CYTARABINE; CYTOKINE; DOXORUBICIN; MITOXANTRONE; PLACEBO; SEMAXANIB; SORAFENIB; SUNITINIB; VATALANIB;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; AUTOCRINE EFFECT; BLOOD VESSEL; BONE MARROW; BONE PAIN; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL FUNCTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; EDEMA; ENDOTHELIUM CELL; FATIGUE; GLIOBLASTOMA; HAND FOOT AND MOUTH DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LEUKEMIA CELL; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MICROVASCULATURE; MOUTH ULCER; PARACRINE SIGNALING; PHENOTYPE; PROGNOSIS; REVIEW; SOLID TUMOR; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

EID: 81555220915     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/128608     Document Type: Review

References (52)

1. Jabbour E. J., Estey E., Kantarjian H. M., Adult acute myeloid leukemia Mayo Clinic Proceedings 2006 81 2 247 260 (Pubitemid 43205780)
2. Lowenberg B., Downing J. R., Burnett A., Acute myeloid leukemia The New England Journal of Medicine 1999 341 14 1051 1062 (Pubitemid 29451802)
3. Appelbaum F. R., Gundacker H., Head D. R., Slovak M. L., Willman C. L., Godwin J. E., Anderson J. E., Petersdorf S. H., Age and acute myeloid leukemia Blood 2006 107 9 3481 3485
4. Hoggatt J., Pelus L. M., Mobilization of hematopoetic stem cells from the bone marrow niche to the blood compartment Stem Cell Research and Therapy 14 2 2 13
5. Ayala F., Dewar R., Kieran M., Kalluri R., Contribution of bone microenvironment to leukemogenesis and leukemia progression Leukemia 2009 23 2233 2241
6. Fiedler W., Graeven U., Ergn S., Verago S., Kilic N., Stockschlder M., Hossfeld D. K., Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia Blood 1997 89 6 1870 1875 (Pubitemid 27132100)
7. Hussong J. W., Rodgers G. M., Shami P. J., Evidence of increased angiogenesis in patients with acute myeloid leukemia Blood 2000 95 1 309 313 (Pubitemid 30017257)
8. Shih T. T. F., Hou H. A., Liu C. Y., Chen B. B., Tang J. L., Chen H. Y., Wei S. Y., Yao M., Huang S. Y., Chou W. C., Hsu S. C., Tsay W., Yu C. W., Hsu C. Y., Tien H. F., Yang P. C., Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival Blood 2009 113 14 3161 3167
9. Padro T., Mesters R. M., Bieker R., Brger H., Steins M., Kienast J., Bchner T., Berdel W. E., Ruiz M. M., Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia Blood 2000 95 8 2637 2644 (Pubitemid 30210544)
10. Kuzu I., Beksac M., Arat M., Celebi H., Elhan A. H., Erekul S., Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival Leukemia and Lymphoma 2004 45 6 1185 1190 (Pubitemid 38584901)
11. Liesveld J. L., Rosell K. E., Lu C., Bechelli J., Phillips G., Lancet J. E., Abboud C. N., Acute myelogenous leukemia-microenvironment interactions: role of endothelial cells and proteasome inhibition Hematology 2005 10 6 483 494 (Pubitemid 43123471)
12. Hatfield K., yan A. M., Ersvaer E., Kalland K. H., Lassalle P., Gjertsen B. T., Bruserud., Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators British Journal of Haematology 2009 144 1 53 68
13. Kruizinga R. C., de Jonge H. J., Kampen K. R., Walenkamp A. M., de Bont E. S., Vascular endothelial growth factor a isoform mRNA expression in pediatric acute myeloid leukemia Pediatric Blood and Cancer 2011 56 2 294 297
14. Perez A. R., Sallan S. E., Tedrow U., Connors S., Allred E., Folkman J., Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia American Journal of Pathology 1997 150 3 815 821 (Pubitemid 27106153)
15. Madlambayan G. J., Meacham A. M., Hosaka K., Mir S., Jorgensen M., Scott E. W., Siemann D. W., Cogle C. R., Leukemia regression by vascular disruption and antiangiogenic therapy Blood 2010 116 9 1539 1547
16. Hou W., Chou W. C., Lin L. I., Tang J. L., Tseng M. H., Huang C. F., Yao M., Chen C. Y., Tsay W., Tien H. F., Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia Leukemia Research 2008 32 6 904 912 (Pubitemid 351392041)
17. Loges S., Heil G., Bruweleit M., Schoder V., Butzal M., Fischer U., Gehling U. M., Schuch G., Hossfeld D. K., Fiedler W., Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival Journal of Clinical Oncology 2005 23 6 1109 1117 (Pubitemid 46202266)
18. Mourah S., Porcher R., Lescaille G., Rousselot P., Podgorniak M. P., Labarchde G., Nami B., Medioni J., Dombret H., Calvo F., Quantification of VEGF isoforms and VEGFR transcripts by qRT-PCR and their significance in acute myeloid leukemia International Journal of Biological Markers 2009 24 1 22 31
19. Padro T., Bieker R., Ruiz S., Steins M., Retzlaff S., Brger H., Bchner T., Kessler T., Herrera F., Kienast J., Mller-Tidow C., Serve H., Berdel W. E., Mesters R. M., Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia Leukemia 2002 16 7 1302 1310
20. Dias S., Hattori K., Zhu Z., Heissig B., Choy M., Lane W., Wu Y., Chadburn A., Hyjek E., Gill M., Hicklin D. J., Witte L., Moore M. A. S., Rafii S., Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration Journal of Clinical Investigation 2000 106 4 511 521 (Pubitemid 30666384)
21. Wakabayashi M., Miwa H., Shikami M., Hiramatsu A., Ikai T., Tajima E., Yamamoto H., Miura K., Satoh A., Itoh M., Imamura A., Mihara H., Katoh Y., Nitta M., Autocrine pathway of angiopoietins-Tie2 system in AML cells The Hematology Journal 2004 5 4 353 360
22. Reikvam H., Hatfield K. J., Lassalle P., Olsnes Kittang A., Ersvr E., Bruserud., Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release Expert Opinion on Investigational Drugs 2010 19 2 169 183
23. Morrissey C., Dowell A., Koreckij T. D., Nguyen H., Lakely B., Fanslow W. C., True L. D., Corey E., Vessella R. L., Inhibition of angiopoietin-2 in Lucap 23.1 prostate cancer tumors decreases tumor growth and viability The Prostate 2010 70 16 1799 1808
24. Skinner A. M., Goldman D. C., McBeth A., Shurtleff M. J., Fleming H. W., Kurre P., Hematopoeitic cells undergo homotypic cell fusion: a novel platform to study genomic instability in leukemogenesis The American Society of Hematology 2010 Orlando, Fla, USA Orange County Convention Center
25. Lancrin C., Sroczynska P., Serrano A. G., Gandillet A., Ferreras C., Kouskoff V., Lacaud G., Blood cell generation from the hemangioblast Journal of Molecular Medicine 2010 88 2 167 172
26. Bailey A., Willenbring H., Jiang S., Anderson D. A., Schroeder D. A., Wong M. H., Grompe M., Fleming W. H., Myeloid lineage progenitors give rise to vascular endothelium Proceedings of the National Academy of Sciences of the United States of America 2006 103 35 13156 13161 (Pubitemid 44338932)
27. Cogle C. R., Wainman D. A., Jorgensen M. L., Guthrie S. M., Mames R. N., Scott E. W., Adult human hematopoietic cells provide functional hemangioblast activity Blood 2004 103 1 133 135 (Pubitemid 38029928)
28. Cogle C. R., Scott E. W., The hemangioblast: cradle to clinic Experimental Hematology 2004 32 10 885 890 (Pubitemid 39410702)
29. Grant M. B., May W. S., Caballero S., Brown G. A. J., Guthrie S. M., Mames R. N., Byrne B. J., Vaught T., Spoerri P. E., Peck A. B., Scott E. W., Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization Nature Medicine 2002 8 6 607 612 (Pubitemid 34633439)
30. Bailey A. S., Jiang S., Afentoulis M., Baumann C. I., Schroeder D. A., Olson S. B., Wong M. H., Fleming W. H., Transplanted adult hematopoietic stems cells differentiate into functional endothelial cells Blood 2004 103 1 13 19 (Pubitemid 38029913)
31. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R. C. H., Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics Blood 2005 105 7 2733 2740 (Pubitemid 40446263)
32. Yoder M. C., Mead L. E., Prater D., Krier T. R., Mroueh K. N., Li F., Krasich R., Temm C. J., Prchal J. T., Ingram D. A., Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals Blood 2007 109 5 1801 1809 (Pubitemid 46348173)
33. Otten J., Schultze A., Schafhausen P., Otterstetter S., Dierlamm J., Bokemeyer C., Brummendorf T. H., Fiedler W., Loges S., Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative British Journal of Haematology 2008 142 1 115 118 (Pubitemid 351783163)
34. Karp J., Gojo I., Pili R., Gocke C. D., Greer J., Guo C., Qian D., Morris L., Tidwell M., Chen H., Zwiebel J., Targeting vascular endothelial growth factor for relapsed and refractory adult acute myelogenous leukemias: therapy with sequential 1- -D-arabinofuranosylcytosine, mitoxantrone, and bevacizumab Clinical Cancer Research 2004 10 11 3577 3585 (Pubitemid 38697590)
35. Mesters R. M., Zahiragic L., Schliemann C., Bieker R., Thoennissen N. H., Burow K., Kramer C., Zhlsdorf M., Berdel W. E., Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity Leukemia 2007 21 6 1310 1312 (Pubitemid 46831824)
36. Lockhart A. C., Rothenberg M. L., Dupont J., Cooper W., Chevalier P., Sternas L., Buzenet G., Koehler E., Sosman J. A., Schwartz L. H., Gultekin D. H., Koutcher J. A., Donnelly E. F., Andal R., Dancy I., Spriggs D. R., Tew W. P., Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors Journal of Clinical Oncology 2010 28 2 207 214
37. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O. G., O'Farrell A. M., Bello C. L., Allred R., Manning W. C., Cherrington J. M., Louie S. G., Hong W., Brega N. M., Massimini G., Scigalla P., Berdel W. E., Hossfeld D. K., A phase I study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease Blood 2005 105 3 986 993 (Pubitemid 40170865)
38. Fiedler W., Mesters R., Tinnefeld H., Loges S., Staib P., Dhrsen U., Flasshove M., Ottmann O. G., Jung W., Cavalli F., Kuse R., Thomalla J., Serve H., O'Farrell A. M., Jacobs M., Brega N. M., Scigalla P., Hossfeld D. K., Berdel W. E., A phase 2 clinical study of SU5416 Blood 2003 102 8 2763 2767
39. Ravandi F., Cortes J. E., Jones D., Faderl S., Garcia-Manero G., Konopleva M. Y., O'Brien S., Estrov Z., Borthakur G., Thomas D., Pierce S. R., Brandt M., Byrd A., Bekele B. N., Pratz K., Luthra R., Levis M., Andreeff M., Kantarjian H. M., Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia Journal of Clinical Oncology 2010 28 11 1856 1862
40. Metzelder S. K., Wollmer E., Neubauer A., Burchert A., Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option Deutsche Medizinische Wochenschrift 2010 135 38 1852 1856
41. Chan E., Mulkerin D., Rothenberg M., Holen K. D., Lockhart A. C., Thomas J., Berlin J., A phase I trial of CEP -701+ gemcitabine in patients with advanced adenocarcinoma of the pancreas Investigational New Drugs 2008 26 3 241 247
42. Giles F. J., Bellamy W. T., Estrov Z., O'Brien S. M., Verstovsek S., Ravandi F., Beran M., Bycott P., Pithavala Y., Steinfeldt H., Reich S. D., List A. F., Yee K. W. L., The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) Leukemia Research 2006 30 7 801 811 (Pubitemid 43816694)
43. Roboz G. J., Giles F. J., List A. F., Cortes J. E., Carlin R., Kowalski M., Bilic S., Masson E., Rosamilia M., Schuster M. W., Laurent D., Feldman E. J., Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome Leukemia 2006 20 6 952 957 (Pubitemid 43797284)
44. Petit I., Karajannis M. A., Loit V., Young L., Butler J., Hooper A. T., Shido K., Steller H., Chaplin D. J., Feldman E., Rafii S., The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death Blood 2008 111 4 1951 1961 (Pubitemid 351451505)
45. Tol J., Punt C. J., Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review Clinical Therapeutics 2010 32 3 437 453
46. Lal D., Park J. A., Marinaro J., Demock K., Perez A. M., Lin M. H., Tian L., Mashtare T. J., Murphy M., Prey J., Wetzler M., Fetterly G. J., Wang E. S., Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models Molecular Cancer Therapeutics 2010 9 10 2737 2751
47. Batchelor T., Duda D. G., di Tomaso E., Ancukiewicz M., Plotkin S. R., Gerstner E., Eichler A. F., Drappatz J., Hochberg F. H., Benner T., Louis D. N., Cohen K. S., Chea H., Exarhopoulos A., Loeffler J. S., Moses M. A., Ivy P., Sorensen A. G., Wen P. Y., Jain R. K., Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma Journal of Clinical Oncology 2010 28 17 2817 2823
48. Goss G., Shepherd F. A., Laurie S., Gauthier I., Leighl N., Chen E., Feld R., Powers J., Seymour L., A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group European Journal of Cancer 2009 45 5 782 788
49. Escudier B., Eisen T., Stadler W. M., Szczylik C., Oudard S., Siebels M., Negrier S., Chevreau C., Solska E., Desai A. A., Rolland F., Demkow T., Hutson T. E., Gore M., Freeman S., Schwartz B., Shan M., Simantov R., Bukowski R. M., Sorafenib in advanced clear-cell renal-cell carcinoma The New England Journal of Medicine 2007 356 2 125 134 (Pubitemid 46089673)
50. Rimassa L., Santoro A., Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial Expert Review of Anticancer Therapy 2009 9 6 739 745
51. Shih T. T., Hou H. A., Liu C. Y., Chen B. B., Tang J. L., Chen H. Y., Wei S. Y., Yao M., Huang S. Y., Chou W. C., Hsu S. C., Tsay W., Yu C. W., Hsu C. Y., Tien H. F., Yang P. C., Bone marrow angiogenesis magnetic resonance imaging in patients with acute myeloid leukemia: peak enhancement ratio is an independent predictor for overall survival Blood 2009 113 14 3161 3167
52. Chen B. B., Hsu C.-Y., Yu C.-W., Hou H.-A., Liu C.-Y., Wei S.-Y., Chou W.-C., Tien H.-F., Shih T. T.-F., Dynamic contrast-enhanced MR imaging measurement of vertebral bone marrow perfusion may be indicator of outcome of acute myeloid leukemia patients in remission Radiology 2011 258 3 821 831